HYPERURICEMIA AS A PREDICTOR OF CHRONIC HEART FAILURE
https://doi.org/10.20996/1819-6446-2015-11-4-355-358
Abstract
Aspects of comorbidity in patients with chronic heart failure are discussed. A focus on hyperuricemia, its effect on the course and prognosis in patients with heart failure, as well as the possibility of its medical correction are maintained.
About the Authors
M. V. Ledyakhova
Institute of Clinical Cardiology named after A.L. Myasnikov, Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
S. N. Nasonova
Institute of Clinical Cardiology named after A.L. Myasnikov, Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
S. N. Tereshchenko
Institute of Clinical Cardiology named after A.L. Myasnikov, Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
References
1. Mareev VY, Ageev FT, Arutyunov GP, et al. National guidelines for diagnosis and treatment of chronic heart failure (fourth revision). Serdechnaya Nedostatochnost' 2013; 14 (7): 1-34. Russian (Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная Недостаточность 2013; 14(7): 1-34).
2. Oshchepkova EV, Lazarev NV, Satlykova DF, Tereschenko SN. The first results of the Russian Register of chronic heart failure. Kardiologiia 2015; 5: 22-8. Russian (Ощепкова Е.В., Лазарева Н.В., Сатлыкова Д.Ф., Терещенко С.Н. Первые результаты Российского регистра хронической сердечной недостаточности. Кардиология 2015; 5: 22-8).
3. van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014;16(1):103-11.
4. Nasonov EL, Nasonova VA, eds. Rheumatology: national leadership. Moscow: GEOTAR Media; 2008. Russian (Насонов Е.Л., Насонова В.А., редакторы. Ревматология: национальное руководство. Москва: ГЭОТАР-Медиа; 2008).
5. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33:1787-847.
6. Anker S.D., Doehner W., Rauchhaus M. et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-7.
7. Martinez A., Gonzalez A., Cerda C., et al. Prognostic value of hyperuricemia in chronic heart failure. Rev Med Chil 2004; 132(9): 1031-6.
8. Pinelli M., Bindi M., Filardo F.P., et al. Serum uric acid levels correlate with left ventricular ejection fraction and systolic pulmonary artery pressure in patients with heart failure. Recenti Prog Med 2007; 98(12): 619-23.
9. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, et al., JCARE-CARD Investigators. Hyperuricemia predicts adverse outcomes in patients with heart failure. J Cardiol 2011;151(2):143-7.
10. Niizeki T, Takeishi Y, Arimoto T, et al. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. J Cardiol 2006;47(5):219-28.
11. Baldasseroni S, Urso R, Maggioni A.P., et al.; IN-CHF Investigators. Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: data from the IN-CHF Registry. Nutr Metab Cardiovasc Dis 2012;22(5):442-8.
12. Severin ES, ed. Biochemistry: Textbook for universities. Moscow: GEOTAR-MED; 2008. Russian (Северин Е.С., ред. Биохимия: Учебник для вузов. Москва: ГЭОТАР-МЕД; 2008).
13. Puzanov OG, Taran AI. Hyperuricemia and cardiovascular continuum. Vnutrennyaya Meditsina 2009; 3 (15): 9-18. Russian (Пузанова О.Г., Таран А.И. Гиперурикемия и кардиоваскулярный континуум. Внутренняя Медицина 2009; 3(15): 9-18).
14. Hare J., Johnson R. Uric acid predicts clinical outcomes in heart failure. Insights regarding the role of xantine oxidase and uric acid in disease pathophysiology. Circulation 2003; 107: 1951-3.
15. Mazzali M., Hughes J., Kim Y.G. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal – independent mechanism. Hypertension 2001; 38 (5): 1101-6.
16. Kang D.H., Nakagawa T., Feng L., et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13(12): 2888-97.
17. Sanchez-Lozada L.G., Tapia E., Santamaria J. et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67(1): 237-47.
18. Kanellis J., Kang D.N. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25(1): 39-42.
19. Hare J M, Mangal B, Brown J, et al.; OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008;51(24):2301-9.
20. Farquharson CA, Butler R, Hill A, et al. Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure. Circulation 2002: 106; 221-6.
21. Struthers A.D., Donnan P.T., Lindsay P, et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 87:229-34.
22. Sinyutina EA, Alexandria LG, Trayanova TG, Moiseev VS. Hyperuricemia in patients with chronic heart failure. Cardiorenal effects of allopurinol. Klinicheskaya Nefrologiya 2012; 2: 46-50. Russian (Синютина Е.А., Александрия Л.Г., Траянова Т.Г., Моисеев В.С. Гиперурикемия при хронической сердечной недостаточности. Кардиоренальные эффекты аллопуринола. Клиническая Нефрология 2012; 2:46-50).
Review
For citations:
Ledyakhova M.V., Nasonova S.N., Tereshchenko S.N. HYPERURICEMIA AS A PREDICTOR OF CHRONIC HEART FAILURE. Rational Pharmacotherapy in Cardiology. 2015;11(4):355-358. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-4-355-358
Views:
839
Email this article 